Puma Biotechnology (PBYI)
Puma Biotechnology on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.5M
Short interest
settlement 2026-10-15
12.9
Days to cover
-1.1 days vs prior
52.4%
Short share of volume
2026-11-03
681
Fails to deliver
settlement 2026-10-13
Thu 5 Nov
Next earnings
estimated date
-$612K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PBYI is 4,540,314 shares, up 220,651 shares over the last month. Over the last 48 readings it ranged from 2,605,080 shares (15 July 2025) to 4,540,314 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 353K shares a day that is 12.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/pbyi" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,540,314 | +6.5% | 352,639 | 12.88 |
| 2026-09-30 | 4,264,923 | -1.3% | 304,289 | 14.02 |
| 2026-09-15 | 4,319,663 | +1.1% | 313,119 | 13.80 |
| 2026-08-31 | 4,274,524 | +2.6% | 273,610 | 15.62 |
| 2026-08-14 | 4,167,830 | +1.0% | 365,781 | 11.39 |
| 2026-07-31 | 4,126,395 | +5.5% | 297,127 | 13.89 |
| 2026-07-15 | 3,909,380 | +7.7% | 367,132 | 10.65 |
| 2026-06-30 | 3,628,478 | -1.9% | 428,367 | 8.47 |
| 2026-06-15 | 3,698,796 | -2.8% | 200,928 | 18.41 |
| 2026-05-29 | 3,803,328 | -9.3% | 192,768 | 19.73 |
| 2026-05-15 | 4,194,225 | +2.2% | 355,790 | 11.79 |
| 2026-04-30 | 4,105,615 | -1.2% | 220,877 | 18.59 |
| 2026-04-15 | 4,156,497 | +5.6% | 329,805 | 12.60 |
| 2026-03-31 | 3,936,887 | -4.2% | 236,626 | 16.64 |
| 2026-03-13 | 4,109,329 | +9.2% | 467,371 | 8.79 |
| 2026-02-27 | 3,764,191 | +2.8% | 501,710 | 7.50 |
| 2026-02-13 | 3,662,823 | +5.2% | 429,824 | 8.52 |
| 2026-01-30 | 3,480,513 | -3.1% | 446,862 | 7.79 |
| 2026-01-15 | 3,591,353 | +4.3% | 363,274 | 9.89 |
| 2025-12-31 | 3,444,842 | +0.4% | 358,631 | 9.61 |
| 2025-12-15 | 3,430,858 | +0.6% | 402,443 | 8.53 |
| 2025-11-28 | 3,411,205 | +2.4% | 405,135 | 8.42 |
| 2025-11-14 | 3,332,897 | -0.3% | 918,744 | 3.63 |
| 2025-10-31 | 3,342,396 | -0.6% | 398,748 | 8.38 |
| 2025-10-15 | 3,360,938 | -4.5% | 475,124 | 7.07 |
| 2025-09-30 | 3,518,135 | +3.6% | 519,569 | 6.77 |
| 2025-09-15 | 3,395,362 | +22.7% | 540,525 | 6.28 |
| 2025-08-29 | 2,766,747 | +4.4% | 762,160 | 3.63 |
| 2025-08-15 | 2,651,003 | -4.8% | 1,085,363 | 2.44 |
| 2025-07-31 | 2,784,330 | +6.9% | 306,179 | 9.09 |
| 2025-07-15 | 2,605,080 | -1.1% | 340,547 | 7.65 |
| 2025-06-30 | 2,633,554 | -1.6% | 302,399 | 8.71 |
| 2025-06-13 | 2,676,107 | -3.9% | 467,186 | 5.73 |
| 2025-05-30 | 2,784,087 | -2.9% | 342,056 | 8.14 |
| 2025-05-15 | 2,867,287 | -2.2% | 386,516 | 7.42 |
| 2025-04-30 | 2,932,616 | +2.2% | 233,892 | 12.54 |
| 2025-04-15 | 2,868,732 | -0.5% | 349,191 | 8.22 |
| 2025-03-31 | 2,883,273 | +3.2% | 358,543 | 8.04 |
| 2025-03-14 | 2,794,988 | -11.5% | 473,278 | 5.91 |
| 2025-02-28 | 3,157,312 | +2.9% | 553,267 | 5.71 |
| 2025-02-14 | 3,068,107 | +2.8% | 248,691 | 12.34 |
| 2025-01-31 | 2,983,741 | -3.0% | 401,582 | 7.43 |
| 2025-01-15 | 3,074,756 | +2.2% | 1,106,691 | 2.78 |
| 2024-12-31 | 3,009,262 | +3.5% | 542,617 | 5.55 |
| 2024-12-13 | 2,906,650 | +3.6% | 477,721 | 6.08 |
| 2024-11-29 | 2,805,904 | -6.0% | 389,601 | 7.20 |
| 2024-11-15 | 2,983,953 | -6.4% | 772,241 | 3.86 |
| 2024-10-31 | 3,188,854 | -11.8% | 194,187 | 16.42 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of PBYI volume is 52.4%, down 10.5 points over the last five sessions. Over the last 30 readings it ranged from 31.7% (28 October 2026) to 81.5% (12 October 2026). The latest reading is 12.4 points below the 30-session average of 64.8%, on 194K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 102K | 194K | 52.4% | 0 |
| 2026-11-02 | 57K | 166K | 34.6% | 86 |
| 2026-10-30 | 77K | 140K | 55.1% | 12,602 |
| 2026-10-29 | 36K | 82K | 43.8% | 51 |
| 2026-10-28 | 75K | 235K | 31.7% | 0 |
| 2026-10-27 | 65K | 103K | 63.0% | 0 |
| 2026-10-26 | 101K | 143K | 70.6% | 0 |
| 2026-10-23 | 180K | 270K | 66.9% | 0 |
| 2026-10-22 | 114K | 161K | 70.7% | 0 |
| 2026-10-21 | 104K | 138K | 75.5% | 0 |
| 2026-10-20 | 107K | 162K | 65.7% | 2,000 |
| 2026-10-19 | 141K | 198K | 71.4% | 0 |
| 2026-10-16 | 106K | 171K | 62.3% | 0 |
| 2026-10-15 | 120K | 166K | 71.9% | 0 |
| 2026-10-14 | 100K | 139K | 72.2% | 0 |
| 2026-10-13 | 77K | 103K | 74.4% | 0 |
| 2026-10-12 | 95K | 116K | 81.5% | 0 |
| 2026-10-09 | 94K | 133K | 70.7% | 0 |
| 2026-10-08 | 103K | 135K | 76.6% | 0 |
| 2026-10-07 | 101K | 145K | 69.9% | 0 |
| 2026-10-06 | 55K | 95K | 58.3% | 5,271 |
| 2026-10-05 | 68K | 101K | 67.1% | 0 |
| 2026-10-02 | 99K | 144K | 69.0% | 0 |
| 2026-10-01 | 116K | 160K | 72.8% | 0 |
| 2026-09-30 | 71K | 107K | 66.6% | 0 |
| 2026-09-29 | 53K | 71K | 74.4% | 0 |
| 2026-09-28 | 40K | 92K | 43.1% | 0 |
| 2026-09-25 | 73K | 94K | 77.1% | 19 |
| 2026-09-24 | 146K | 238K | 61.4% | 540 |
| 2026-09-23 | 145K | 198K | 73.0% | 7 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in PBYI is 681 shares, up 634 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (5 March 2026) to 6,693 shares (14 October 2025).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 681 | $10.29 | $7K |
| 2026-10-01 | 47 | $9.93 | $467 |
| 2026-08-17 | 692 | $8.83 | $6K |
| 2026-06-30 | 5,289 | $8.19 | $43K |
| 2026-06-29 | 83 | $8.11 | $673 |
| 2026-06-12 | 118 | $7.23 | $853 |
| 2026-06-09 | 129 | $6.85 | $884 |
| 2026-06-04 | 856 | $6.81 | $6K |
| 2026-05-22 | 6,122 | $7.05 | $43K |
| 2026-04-16 | 1,746 | $7.48 | $13K |
| 2026-03-24 | 307 | $6.25 | $2K |
| 2026-03-05 | 1 | $6.40 | $6 |
| 2026-02-03 | 320 | $6.82 | $2K |
| 2026-02-02 | 320 | $6.48 | $2K |
| 2026-01-08 | 43 | $6.09 | $262 |
| 2025-12-29 | 83 | $6.16 | $511 |
| 2025-12-24 | 6,511 | $5.91 | $38K |
| 2025-11-10 | 2,508 | $5.99 | $15K |
| 2025-10-24 | 2,722 | $5.04 | $14K |
| 2025-10-22 | 317 | $5.17 | $2K |
| 2025-10-20 | 4,850 | $5.47 | $27K |
| 2025-10-14 | 6,693 | $5.29 | $35K |
| 2025-10-03 | 25 | $5.22 | $131 |
| 2025-09-30 | 15 | $5.05 | $76 |
| 2025-09-24 | 1,562 | $4.71 | $7K |
| 2025-09-16 | 173 | $4.64 | $803 |
| 2025-08-19 | 2,049 | $5.01 | $10K |
| 2025-08-18 | 288 | $5.73 | $2K |
| 2025-08-13 | 3,755 | $4.87 | $18K |
| 2025-06-26 | 3,261 | $3.31 | $11K |
Insider trades
SEC Form 4, newest first. JSONInsiders at PBYI reported 2 open-market sells worth $612K in the last 90 days and no open-market buys. Latest filing: Cesano Alessandra (Director) on 2026-09-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Cesano Alessandra | Director | Sell | 62K | $9.12 | $567K | 57K |
| 2026-09-14 | Cesano Alessandra | Director | Exercise or conversion | 50K | $2.93 | $147K | 119K |
| 2026-09-14 | WILSON TROY EDWARD | Director | Sell | 5K | $9.10 | $46K | 55K |
| 2026-07-06 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 9K | $8.26 | $78K | 231K |
| 2026-07-06 | HUNT DOUGLAS M | See Remarks | Sell | 8K | $8.26 | $70K | 197K |
| 2026-07-06 | AUERBACH ALAN H | President and CEO | Sell | 44K | $8.26 | $364K | 7.3M |
| 2026-06-12 | Dorval Allison | Director | Sell | 12K | $7.20 | $84K | 91K |
| 2026-06-12 | MOYES JAY M | Director | Sell | 22K | $7.22 | $159K | 58K |
| 2026-06-12 | Senderowicz Adrian | Director | Sell | 27K | $7.20 | $194K | 27K |
| 2026-06-12 | Stuglik Brian M | Director | Sell | 8K | $7.20 | $58K | 114K |
| 2026-06-12 | WILSON TROY EDWARD | Director | Sell | 11K | $7.20 | $78K | 60K |
| 2026-06-11 | Cesano Alessandra | Director | Grant | 27K | $0.00 | $0 | 69K |
| 2026-06-11 | Dorval Allison | Director | Grant | 27K | $0.00 | $0 | 102K |
| 2026-06-11 | MOYES JAY M | Director | Grant | 27K | $0.00 | $0 | 80K |
| 2026-06-11 | MILLER MICHAEL PATRICK | Director | Grant | 27K | $0.00 | $0 | 81K |
| 2026-06-11 | Senderowicz Adrian | Director | Grant | 27K | $0.00 | $0 | 54K |
| 2026-06-11 | Stuglik Brian M | Director | Grant | 27K | $0.00 | $0 | 122K |
| 2026-06-11 | WILSON TROY EDWARD | Director | Grant | 27K | $0.00 | $0 | 71K |
| 2026-02-18 | NOUGUES MAXIMO F | Chief Financial Officer | Grant | 47K | $0.00 | $0 | 240K |
| 2026-02-18 | HUNT DOUGLAS M | See Remarks | Grant | 49K | $0.00 | $0 | 205K |
| 2026-02-18 | AUERBACH ALAN H | President and CEO | Grant | 160K | $0.00 | $0 | 7.3M |
| 2026-01-07 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 6K | $5.88 | $38K | 193K |
| 2026-01-07 | HUNT DOUGLAS M | See Remarks | Sell | 5K | $5.88 | $29K | 156K |
| 2026-01-07 | AUERBACH ALAN H | President and CEO | Sell | 18K | $5.88 | $106K | 7.1M |
| 2026-01-06 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 5K | $5.84 | $27K | 200K |
| 2026-01-06 | HUNT DOUGLAS M | See Remarks | Sell | 4K | $5.84 | $23K | 161K |
| 2026-01-06 | AUERBACH ALAN H | President and CEO | Sell | 17K | $5.84 | $99K | 7.2M |
| 2025-11-11 | MILLER MICHAEL PATRICK | Director | Sell | 20K | $4.86 | $97K | 54K |
| 2025-07-18 | Cesano Alessandra | Director | Sell | 27K | $3.37 | $91K | 42K |
| 2025-07-09 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 4K | $3.54 | $14K | 204K |
| 2025-07-09 | HUNT DOUGLAS M | See Remarks | Sell | 3K | $3.54 | $12K | 165K |
| 2025-07-09 | AUERBACH ALAN H | President and CEO | Sell | 22K | $3.54 | $76K | 7.2M |
| 2025-07-08 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 6K | $3.53 | $20K | 208K |
| 2025-07-08 | HUNT DOUGLAS M | See Remarks | Sell | 4K | $3.53 | $15K | 168K |
| 2025-07-08 | AUERBACH ALAN H | President and CEO | Sell | 26K | $3.53 | $90K | 7.2M |
| 2025-06-13 | WILSON TROY EDWARD | Director | Sell | 11K | $3.40 | $37K | 44K |
| 2025-06-13 | Stuglik Brian M | Director | Sell | 8K | $3.39 | $27K | 95K |
| 2025-06-13 | Senderowicz Adrian | Director | Sell | 27K | $3.40 | $92K | 27K |
| 2025-06-13 | MOYES JAY M | Director | Sell | 22K | $3.40 | $75K | 53K |
| 2025-06-13 | Dorval Allison | Director | Sell | 12K | $3.40 | $39K | 75K |
| 2025-06-13 | Cesano Alessandra | Director | Sell | 12K | $3.40 | $41K | 69K |
| 2025-06-11 | Senderowicz Adrian | Director | Grant | 27K | $0.00 | $0 | 54K |
| 2025-06-11 | Stuglik Brian M | Director | Grant | 27K | $0.00 | $0 | 103K |
| 2025-06-11 | WILSON TROY EDWARD | Director | Grant | 27K | $0.00 | $0 | 54K |
| 2025-06-11 | MOYES JAY M | Director | Grant | 27K | $0.00 | $0 | 75K |
| 2025-06-11 | MILLER MICHAEL PATRICK | Director | Grant | 27K | $0.00 | $0 | 74K |
| 2025-06-11 | Dorval Allison | Director | Grant | 27K | $0.00 | $0 | 87K |
| 2025-06-11 | Cesano Alessandra | Director | Grant | 27K | $0.00 | $0 | 81K |
| 2025-02-07 | AUERBACH ALAN H | President and CEO | Grant | 198K | $0.00 | $0 | 7.2M |
| 2025-02-07 | HUNT DOUGLAS M | See Remarks | Grant | 48K | $0.00 | $0 | 173K |
| 2025-02-07 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Grant | 48K | $0.00 | $0 | 157K |
| 2025-02-07 | NOUGUES MAXIMO F | Chief Financial Officer | Grant | 61K | $0.00 | $0 | 214K |
| 2025-01-02 | AUERBACH ALAN H | President and CEO | Sell | 34K | $3.15 | $107K | 7.0M |
| 2025-01-02 | HUNT DOUGLAS M | See Remarks | Sell | 9K | $3.15 | $27K | 125K |
| 2025-01-02 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Sell | 9K | $3.15 | $30K | 109K |
| 2025-01-02 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 10K | $3.15 | $32K | 152K |
| 2024-08-12 | MILLER MICHAEL PATRICK | Director | Sell | 23K | $3.49 | $82K | 47K |
| 2024-07-17 | AUERBACH ALAN H | President and CEO | Sell | 22K | $3.70 | $81K | 7.1M |
| 2024-07-17 | HUNT DOUGLAS M | See Remarks | Sell | 4K | $3.70 | $13K | 133K |
| 2024-07-17 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Sell | 3K | $3.70 | $10K | 118K |
| 2024-07-17 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 4K | $3.70 | $15K | 163K |
| 2024-07-02 | AUERBACH ALAN H | President and CEO | Sell | 19K | $3.27 | $62K | 7.1M |
| 2024-07-02 | HUNT DOUGLAS M | See Remarks | Sell | 4K | $3.27 | $14K | 137K |
| 2024-07-02 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Sell | 6K | $3.27 | $20K | 121K |
| 2024-07-02 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 5K | $3.27 | $17K | 167K |
| 2024-06-18 | Cesano Alessandra | Director | Grant | 27K | $0.00 | $0 | 54K |
| 2024-06-18 | Dorval Allison | Director | Grant | 27K | $0.00 | $0 | 60K |
| 2024-06-18 | MOYES JAY M | Director | Grant | 27K | $0.00 | $0 | 48K |
| 2024-06-18 | MILLER MICHAEL PATRICK | Director | Grant | 27K | $0.00 | $0 | 95K |
| 2024-06-18 | Senderowicz Adrian | Director | Grant | 27K | $0.00 | $0 | 27K |
| 2024-06-18 | Stuglik Brian M | Director | Grant | 27K | $0.00 | $0 | 76K |
| 2024-06-18 | WILSON TROY EDWARD | Director | Grant | 27K | $0.00 | $0 | 27K |
| 2024-06-13 | Dorval Allison | Director | Sell | 11K | $3.37 | $37K | 33K |
| 2024-06-13 | MOYES JAY M | Director | Sell | 22K | $3.34 | $73K | 21K |
| 2024-06-13 | Senderowicz Adrian | Director | Sell | 27K | $3.33 | $90K | 0 |
| 2024-06-13 | Stuglik Brian M | Director | Sell | 10K | $3.39 | $34K | 49K |
| 2024-06-13 | WILSON TROY EDWARD | Director | Sell | 27K | $3.33 | $90K | 350 |
| 2024-03-15 | AUERBACH ALAN H | President and CEO | Grant | 7K | $0.00 | $0 | 7.1M |
| 2024-02-12 | HUNT DOUGLAS M | See Remarks | Grant | 38K | $0.00 | $0 | 141K |
| 2024-02-12 | AUERBACH ALAN H | President and CEO | Grant | 161K | $0.00 | $0 | 7.1M |
| 2024-02-12 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Grant | 27K | $0.00 | $0 | 127K |
| 2024-02-12 | NOUGUES MAXIMO F | Chief Financial Officer | Grant | 43K | $0.00 | $0 | 172K |
| 2024-02-12 | Wong Alvin F | Chief Scientific Officer | Grant | 43K | $0.00 | $0 | 141K |
| 2024-01-03 | HUNT DOUGLAS M | See Remarks | Sell | 8K | $4.49 | $38K | 103K |
| 2024-01-03 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 16K | $4.49 | $70K | 129K |
| 2024-01-03 | AUERBACH ALAN H | President and CEO | Sell | 41K | $4.49 | $186K | 6.9M |
| 2024-01-03 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Sell | 13K | $4.49 | $58K | 100K |
| 2024-01-03 | Wong Alvin F | Chief Scientific Officer | Sell | 8K | $4.49 | $35K | 98K |
| 2023-12-04 | Wong Alvin F | Chief Scientific Officer | Sell | 280 | $3.76 | $1K | 98K |
| 2023-11-07 | MILLER MICHAEL PATRICK | Director | Sell | 25K | $2.83 | $71K | 43K |
| 2023-07-03 | AUERBACH ALAN H | President and CEO | Sell | 61K | $3.31 | $201K | 7.0M |
| 2023-07-03 | HUNT DOUGLAS M | See Remarks | Sell | 8K | $3.31 | $26K | 112K |
| 2023-07-03 | Ludwig Jeffrey Jerome | Chief Commercial Officer | Sell | 12K | $3.31 | $40K | 113K |
| 2023-07-03 | NOUGUES MAXIMO F | Chief Financial Officer | Sell | 15K | $3.31 | $49K | 144K |
| 2023-07-03 | Wong Alvin F | Chief Scientific Officer | Sell | 7K | $3.31 | $23K | 106K |
| 2023-06-13 | Cesano Alessandra | Director | Grant | 27K | $0.00 | $0 | 27K |
| 2023-06-13 | MILLER MICHAEL PATRICK | Director | Grant | 27K | $0.00 | $0 | 68K |
| 2023-06-13 | MILLER MICHAEL PATRICK | Director | Sell | 14K | $3.45 | $47K | 41K |
| 2023-06-13 | Dorval Allison | Director | Grant | 27K | $0.00 | $0 | 44K |
| 2023-06-13 | Dorval Allison | Director | Sell | 10K | $3.45 | $35K | 17K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON17 Form 144 notices on file for PBYI worth $2.1M at the prices reported; 2 in the last 90 days worth $611K. Latest: WILSON TROY EDWARD filed on 2026-09-14 to sell 5,000 shares ($46K) from 2026-09-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-14 | WILSON TROY EDWARDDirector | 5K | $46K | 0.010% | 2026-09-14 | Fidelity Brokerage Services LLC |
| 2026-09-14 | Cesano AlessandraDirector | 62K | $566K | 0.120% | 2026-09-14 | Fidelity Brokerage Services LLC |
| 2026-07-06 | NOUGUES MAXIMO FOfficer | 9K | $78K | 0.018% | 2026-07-06 | Fidelity Brokerage Services LLC |
| 2026-07-06 | HUNT DOUGLAS MOfficer | 8K | $70K | 0.017% | 2026-07-06 | Fidelity Brokerage Services LLC |
| 2026-07-06 | AUERBACH ALAN HOfficer, Director | 44K | $364K | 0.087% | 2026-07-06 | Fidelity Brokerage Services LLC |
| 2026-06-12 | Senderowicz AdrianDirector | 27K | $196K | 0.053% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-06-12 | Stuglik Brian MDirector | 8K | $59K | 0.016% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-06-12 | WILSON TROY EDWARDDirector | 11K | $78K | 0.021% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-06-12 | MOYES JAY MDirector | 22K | $160K | 0.043% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-06-12 | Dorval AllisonDirector | 12K | $84K | 0.023% | 2026-06-12 | Fidelity Brokerage Services LLC |
| 2026-01-07 | NOUGUES MAXIMO FOfficer | 6K | $38K | 0.013% | 2026-01-07 | Fidelity Brokerage Services LLC |
| 2026-01-07 | HUNT DOUGLAS MOfficer | 5K | $29K | 0.010% | 2026-01-07 | Fidelity Brokerage Services LLC |
| 2026-01-07 | AUERBACH ALAN HOfficer, Director | 18K | $106K | 0.036% | 2026-01-07 | Fidelity Brokerage Services LLC |
| 2026-01-06 | NOUGUES MAXIMO FOfficer | 5K | $27K | 0.009% | 2026-01-06 | Fidelity Brokerage Services LLC |
| 2026-01-06 | HUNT DOUGLAS MOfficer | 4K | $23K | 0.008% | 2026-01-06 | Fidelity Brokerage Services LLC |
| 2026-01-06 | AUERBACH ALAN HOfficer, Director | 17K | $99K | 0.034% | 2026-01-06 | Fidelity Brokerage Services LLC |
| 2025-11-12 | MILLER MICHAEL PATRICKDirector | 20K | $97K | 0.040% | 2025-11-11 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of PBYI in its latest filing, on Schedule 13D (active intent). The holder is Alan H. Auerbach at 16.0% of the class (8,648,958 shares), filed 2026-10-06 for an event on 2026-10-04.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-06 | 13D/Ano. 6 | Alan H. Auerbachindividual | 8.6M | 16.0% | 2026-10-04 |
| 2026-03-27 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding PBYI at their latest 13F. JSON5 of the 30 tracked managers held PBYI at their latest 13F, $29.4M in total at quarter-end prices. Renaissance Technologies is the largest at $14.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 1.8M | $14.9M | 0.02% | -106K |
| AQR Capital Management | 2026-06-30 | 725K | $5.9M | 0.00% | -75K |
| Millennium Management | 2026-06-30 | 602K | $4.9M | 0.00% | -875K |
| D. E. Shaw & Co. | 2026-06-30 | 316K | $2.6M | 0.00% | -35K |
| Two Sigma Investments | 2026-06-30 | 141K | $1.1M | 0.00% | +128K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Puma Biotechnology in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Puma Biotechnology (PBYI), SEC CIK 1401667, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1401667Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of PBYI is sold short?
4,540,314 shares were held short at the 2026-10-15 settlement, 12.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PBYI's daily short volume?
On 2026-11-03, 101,859 of the 194,298 PBYI shares reported to FINRA were sold short, 52.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PBYI have fails to deliver?
The SEC's latest file shows 681 PBYI shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are PBYI insiders buying or selling?
Insiders at PBYI reported 2 open-market sells worth $612K in the last 90 days and no open-market buys. Latest filing: Cesano Alessandra (Director) on 2026-09-14.
Have PBYI insiders filed to sell?
17 Form 144 notices on file for PBYI worth $2.1M at the prices reported; 2 in the last 90 days worth $611K. Latest: WILSON TROY EDWARD filed on 2026-09-14 to sell 5,000 shares ($46K) from 2026-09-14.
Who owns 5% or more of PBYI?
1 holder reports 5% or more of PBYI in its latest filing, on Schedule 13D (active intent). The holder is Alan H. Auerbach at 16.0% of the class (8,648,958 shares), filed 2026-10-06 for an event on 2026-10-04.
Which tracked 13F managers own PBYI?
5 of the 30 tracked 13F managers held PBYI shares at their latest filing, $29.4M in all. The largest: Renaissance Technologies (1.8M shares, $14.9M), Cliff Asness's AQR Capital Management (725K shares, $5.9M), Izzy Englander's Millennium Management (602K shares, $4.9M), D. E. Shaw & Co. (316K shares, $2.6M), Two Sigma Investments (141K shares, $1.1M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.